Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721918 | 0.93 | PTGS2 (0.65) | PTGS2PTGS1PDPK1CYP2C9CYP1A2 | |
| SCHEMBL6729339 | 0.92 | PTGS2 (0.57) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6718487 | 0.91 | PTGS2 (0.74) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL6724028 | 0.90 | PTGS2 (0.63) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6723842 | 0.90 | PTGS2 (0.66) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL6721886 | 0.90 | PTGS2 (0.73) | PTGS2PTGS1PDPK1CYP2C9CYP3A4 | |
| SCHEMBL6725929 | 0.90 | PTGS2 (0.61) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6723628 | 0.90 | PTGS2 (0.61) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6723633 | 0.89 | PTGS2 (0.57) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6723564 | 0.89 | PTGS2 (0.62) | PTGS2PTGS1PDPK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885PDPK1 3101/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885PDPK1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.